Barclays lowered the firm’s price target on Tandem Diabetes (TNDM) to $53 from $60 and keeps an Overweight rating on the shares. The company reported mixed results and in-line guidance, but nothing likely justifies the 30% drop in the stock, the analyst tells investors in a research note. The firm believes Tandem’s “strong pipeline and beatable outlook” position the stock go higher.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Record Sales and Strategic Growth
- Tandem Diabetes price target lowered to $55 from $65 at RBC Capital
- Tandem Diabetes price target lowered to $33 from $37 at Baird
- Sell Rating for Tandem Diabetes Care Due to Revenue Shortfalls and High Valuation
- Tandem Diabetes price target lowered to $58 from $63 at Canaccord
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue